Somaform's Interface Line Draws a Second Look From the Regulators

FRANKFURT — Six weeks after Brazil voted a ceiling over the deepest classes of augmentation, the question moved from the ballot box to the workbench: a Concordat-level medical regulator opened a routine safety review this week of a Somaform Augmetics neural-interface line, examining a cluster of reported calibration faults in one of the firm's high-bandwidth models. Somaform, whose founder Julian Morrow has spent a decade as the loudest voice for augmentation as a right, welcomed the review in the careful language of a company that knows the timing looks pointed. "A safety review is not a verdict, and we asked for the data as loudly as anyone," Morrow said from Frankfurt. "The line is safe. The review will say so. And we would rather it say so than assume it." The review reopens augmentation's oldest and least answerable question — how much enhancement is too much, and whose hand belongs on the dial — in the weeks after a continent tried to answer it by law. Regulators stressed the review is standard post-market surveillance, not a response to any single incident. The distinction matters to Somaform. It matters less, this week, to a public that has spent a month deciding it is allowed to worry out loud.